Krithika Subramanian, PhD

Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.

Less than 5 years after BTK inhibition was introduced in hematologic malignancies, the need for strategies to address primary and secondary mechanisms of resistance has emerged.